PharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing Facility
PR Newswire•09/11/2026•16:05 ET
0
Key Highlights
- ➤PharmaLogic to acquire Lantheus (LNTH) CDMO business and Springfield manufacturing facility
- ➤Transaction financial terms were not disclosed
- ➤Lantheus will receive long-term Lu 177 dotatate manufacturing supply from Agilera
- ➤Springfield facility creates PharmaLogic’s first transatlantic therapeutic CDMO platform
- ➤Transaction remains subject to regulatory review and customary closing conditions
Expert Statements
Etienne Montagut, President and Chief Executive Officer of PharmaLogic
“This acquisition strengthens Agilera's unique capabilities in radioligand therapies and expands our capacity in the U.S.”
Etienne Montagut, President and Chief Executive Officer of PharmaLogic
“We are proud to welcome the talented Springfield team, who will help us scale our operations to meet growing demand from our partners and the patients they serve.”
Mary Anne Heino, Executive Chairperson and Chief Executive Officer of Lantheus
“With its proven radiopharmaceutical expertise and manufacturing capabilities, PharmaLogic is the right long-term owner for the CDMO business and Springfield facility, with the capabilities to build on this foundation while supporting reliable supply of our newly approved radiotherapeutic for patients and healthcare providers.”
PharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing Facility PR Newswire
Expands U.S. therapeutic manufacturing capacity and creates the first transatlantic CDMO platform with a proven commercial track record in radioligand therapies
Get started
Create a free account to read the full story.